The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://hyperbookmarks.com/story20700154/retatrutide-vs-tirzepatide-a-comparative-analysis